In partnership with
September 2, 2025
Built by a former cannabis regulator, Policy, Decoded is your high-signal daily briefing for operators, investors, and policymakers navigating the collision of law, regulation, and business.
Today’s edition is supported by Superhuman AI, the newsletter helping over a million professionals stay ahead of AI tools, trends, and skills in just minutes a day.
A new Emerson poll confirms two-thirds of voters now back cannabis legalization nationwide, putting Trump in control of the most consequential policy shift in fifty years. California’s Senate froze its cannabis tax hike while advancing hemp regulation, Texas expanded medical access with 12 new licenses, and Missouri operators are positioning for a rescheduling windfall. Meanwhile, Schwazze’s restructuring highlights the debt avalanche, investors are flooding into the MSOS ETF, and Canadian spending data underscores how legal markets can win when regulators clear the path. Our deep dive looks at how California’s broken economics are fueling a surge in cannabis smuggling into the UK — proof that oversupply and overtaxation don’t stay local.
📊 Track polling momentum that reshapes political risk
💰 Follow shifting tax, debt, and capital pressures
🌍 Watch U.S. oversupply spill into global markets
Start smarter. Move faster. Stay ahead.
Go from AI overwhelmed to AI savvy professional
AI keeps coming up at work, but you still don't get it?
That's exactly why 1M+ professionals working at Google, Meta, and OpenAI read Superhuman AI daily.
Here's what you get:
Daily AI news that matters for your career - Filtered from 1000s of sources so you know what affects your industry.
Step-by-step tutorials you can use immediately - Real prompts and workflows that solve actual business problems.
New AI tools tested and reviewed - We try everything to deliver tools that drive real results.
All in just 3 minutes a day
Start here — the day’s most important development, decoded for impact.
📌 What Happened: A new Emerson College poll shows 65% of registered voters support legalizing marijuana nationwide, up five percentage points since October, as Trump faces growing pressure to decide on rescheduling within his promised "next few weeks" timeline. Support breaks down with Democrats at 79%, independents at 66%, and Republicans at 49%, while majority support extends across all age groups except those 70 and older. The polling comes as Trump confirmed his administration is "looking at" rescheduling cannabis from Schedule 1 to Schedule 3, with the decision process stalled since January when a DEA administrative law judge canceled hearings. Recent Gallup polling found 70% national support with majorities across all demographics, while Pew Research shows 87% support some form of legalization. Cannabis crosses generational lines from Boomers who experienced the counterculture era to seniors discovering medical benefits, veterans seeking PTSD alternatives, and younger generations choosing cannabis over alcohol.
💡 Why It Matters: Trump faces a rare political winner where reform could significantly boost his approval ratings amid stagnant polling numbers, but the gap between modest rescheduling and full legalization creates strategic complexity. Emerson's Spencer Kimball noted that "if Trump was to make a decision and legalize it, boy, that could really turn things around on his favorability", while cannabis industry stakeholders estimate 280E tax elimination could save operators billions annually, with some companies facing $80-100 million in annual tax burdens. The rescheduling process initiated under Biden remains administratively paused, giving Trump control over timing and scope, but congressional Republicans have filed legislation to maintain 280E tax burdens even if rescheduling occurs. The broad polling support reflects cannabis's unique ability to unite diverse constituencies around personal freedom, medical access, and criminal justice reform - making it potentially transformative for Trump's political brand.
🧠 THC Group Take: Trump holds the keys to the most significant federal cannabis policy shift in 50 years, with polling showing he'd be rewarded for bold action rather than incremental change. The 65% legalization support versus his rescheduling consideration shows he's playing it safe when he could be claiming credit for a generational policy win. Roger Stone's recent op-ed calling rescheduling "the critical next step" toward full descheduling signals Trump allies see political upside in cannabis reform. The cross-demographic appeal - from military veterans to senior citizens to young professionals - creates a coalition that transcends traditional partisan lines. Smart political observers should watch whether Trump chooses the cautious rescheduling path or recognizes that two-thirds support gives him cover for more comprehensive reform. Either way, the cannabis industry will never be the same, but Trump's legacy depends on whether he seizes the full political opportunity or settles for half-measures that satisfy neither prohibitionists nor reformers.
Fast-moving headlines, flagged for what matters.
California's Senate Appropriations Committee approved Assemblymember Matt Haney's bill to pause the cannabis excise tax increase from 19% back to 15% for five years, though the panel moved to "shorten the period that the 15 percent tax rate would be in effect, and add a reporting requirement" with details pending. The tax hike officially took effect in July despite Governor Newsom's support for delaying it, after Senate President Pro Tempore Mike McGuire reportedly blocked the freeze from budget legislation. Senators also unanimously passed legislation to integrate hemp-derived cannabinoid products into the state's regulated cannabis program while banning synthetically derived cannabinoids. The moves signal California's recognition that overtaxing legal cannabis strengthens illicit markets, but McGuire's earlier resistance suggests this isn't over. The hemp integration represents a strategic shift toward regulatory coherence rather than the current patchwork that lets untested products flood the market. (Marijuana Moment)
Illinois cannabis companies are fighting state regulators for outdoor growing rights, with indoor operations costing $5-10 million versus $250,000 for outdoor structures like hoop houses. Two companies won court battles after the state tried revoking previously granted outdoor permits, while Curaleaf has sued for hoop house approval. The Illinois Department of Agriculture argues that structures without solid walls face "challenges including the need to mitigate the impacts of animal and insect life and the chemicals designed to protect against them", highlighting real quality control issues with outdoor cultivation. A UC Berkeley study found outdoor growing could cut emissions by 76% compared to indoor facilities. While consumers increasingly demand sun-grown cannabis and craft growers need cost-effective options, outdoor cultivation presents legitimate contamination risks from pesticide drift, pests, and weather that indoor facilities avoid - creating tension between cost savings and consistent product quality that regulators must navigate. (Chicago Tribune)
Texas's medical marijuana expansion officially took effect Monday, adding chronic pain, traumatic brain injury, and Crohn's disease to qualifying conditions while authorizing 12 new dispensary licenses beyond the current three statewide. A new NuggMD poll shows 91% of consumers believe cannabis effectively treats chronic pain, with 65% calling it "very effective" and only 4% saying it's "not sufficiently effective". The timing coincides with ongoing legislative battles over hemp THC products, as the Senate again passed a ban measure while the House remains divided. NuggMD's Andrew Graham noted that "at least two million Texans use cannabis regularly" but the reformed law provides "an effective, non-addictive option for pain relief that has never directly caused an overdose fatality". The expansion represents incremental progress in a state where political reality forces conservatives to choose between regulated medical access and unregulated hemp chaos. (Marijuana Moment)
Rhode Island's Cannabis Control Commission launched its online certification portal for social equity license applicants seeking six specialty retail licenses out of 24 total new permits. The screening precedes the actual application window, which regulators haven't announced yet. Qualifying factors include convictions for nonviolent cannabis offenses or residency in disproportionately impacted areas determined by federal poverty level, unemployment rate, and historic arrest rates by census tract. Only three municipalities met the full criteria for social equity zones: Central Falls, Providence and Woonsocket. The hybrid selection process screens applicants for qualifications before placing them in a lottery, with application fees waived for approved social equity applicants. While Rhode Island follows the familiar social equity playbook, their pre-screening approach could reduce the administrative chaos that has plagued other states when unqualified applicants flood licensing windows. (Rhode Island Current)
Delaware's cannabis zoning fight deepened Friday as Senate Democrats Chief of Staff Jesse Chadderdon directly contradicted Governor Meyer's denial of a legislative deal over marijuana buffer zones. Chadderdon described "a deal that ended in a handshake and a hug" between Senator Paradee and the governor's policy director that was "discussed repeatedly" with multiple staff members, after Meyer claimed Thursday "I had no agreement with Sen. Paradee" when vetoing the zoning bill. The vetoed legislation would have capped county buffer zones at 500 feet, challenging Sussex County's 3-mile restriction that effectively blocks all 10 license holders from opening. Chadderdon warned that "there's not a ton of trust" and suggested the governor is either "being unfortunately dishonest with the public" or "throwing staff under the bus". The public contradiction between executive and legislative staff creates a precedent for how political dysfunction can paralyze cannabis market implementation even after programs appear settled. (Delaware Public Media)
Missouri's cannabis industry is positioning for major growth as Trump hints at federal rescheduling decisions "in weeks," with the state generating over $100 million monthly and $4.28 billion in cumulative sales since 2018 legalization. MoCannTrade's Jack Cardetti noted that operators are "effectively paying a 70% tax to the federal government" under current Schedule 1 classification, making rescheduling critical for long-term viability. The Wall Street Journal called Missouri a "cannabis mecca" this spring, with the state projected to sell $1.5-1.6 billion in 2025. Cannabis attorney Dan Viets predicted rescheduling could drive retail prices down "by 25% or possibly even more" as businesses gain normal tax deductions. Missouri's aggressive expansion strategy and low regulatory barriers positioned it perfectly to capitalize on federal tax relief that could cement its competitive advantage over more restrictive states. (KOMU 8)
Cornbread Hemp announced the first-ever THC beverage sponsorship in Division I college athletics with the University of Louisville, marking a significant shift in cannabis normalization strategy. The Kentucky-based company, named the state's fastest growing business by Inc. 5000 in 2024, is leveraging Louisville's bourbon heritage narrative to position hemp-derived THC seltzers as the next evolution in adult beverages. This follows USC's CBD sponsorship with Cookies last year, but THC products represent a bigger regulatory and cultural leap. The timing aligns with hemp-derived THC's legal gray area under the 2018 Farm Bill - federally legal products containing less than 0.3% THC that bypass state cannabis programs entirely. What's strategically significant isn't just the sponsorship itself, but how mainstream institutions are now comfortable associating with psychoactive cannabis products, signaling accelerated normalization beyond the traditional CBD playbook. (Cannabis Business Times)
Americans for Safe Access founder Steph Sherer laid out a "bold, beautiful strategy" for Trump's medical cannabis policy, arguing that rescheduling alone won't fix systemic challenges since Schedule 3 won't make state-licensed businesses "legal" under federal law or restore federal rights for patients. Her four-point plan includes finishing DEA rescheduling, removing congressional funding prohibitions, creating an Office of Medical Cannabis at HHS, and establishing a dedicated "Schedule VI" for cannabis. She noted that counties with cannabis dispensaries see opioid death rates drop by about 30 percent within 10 years, connecting to Trump's previous opioid epidemic focus. The pitch reflects a strategic miscalculation common in advocacy - assuming Trump will reschedule and then telling him what comes next. In Washington, presuming decisions before they're made often backfires, especially with a president who values being seen as the decision-maker rather than following predetermined roadmaps. (The Hill)
Cannabis operator Schwazze is finalizing a debt restructuring that will wipe out shareholders while surrendering some of its more than 60 retail locations in exchange for a $65 million cash infusion. Senior lenders will acquire properties through an Article 9 process, which is faster and less expensive than Chapter 11 proceedings, since the company cannot file for bankruptcy protection due to the absence of federal legislation governing cannabis. The deal eliminates both common and preferred shares, with approximately $45 million used to refinance "seller notes" and remaining funds for working capital. This is what happens when SPAC-era expansion meets today's debt reality - operators who built empires on cheap money now face impossible loads. The Article 9 workaround shows how federal prohibition actually makes restructurings more brutal for equity holders, since traditional bankruptcy protections don't exist for cannabis companies. (Investing.com)
Cannabis investors are piling into MSOS ETF betting on Trump administration rescheduling, with the fund seeing a 27.2% increase in shares outstanding and inflows of about $165 million since July amid optimism about 280E tax removal. Some holdings have risen over 300% since mid-year as MSOS aggressively increased positions across its portfolio, though the fund remains highly concentrated with top six holdings comprising 88% of the portfolio. The rally reflects investor belief that rescheduling to Schedule 3 would remove Section 280E tax burden and boost sector profitability, with one operator estimating it would have saved over $80 million in 2023 taxes alone. However, MSOS's extreme concentration in just a few multi-state operators makes it a leveraged bet on rescheduling rather than a diversified cannabis play - if 280E remains, the fund could hit new lows as overleveraged operators face debt service challenges. (Seeking Alpha)
Canadian household cannabis spending reached over $1.7 billion in Q2 2025, with $1.6 billion from adult-use and $119 million from medical markets, according to Statistics Canada's latest GDP data. The legal adult-use market continues growing after surpassing the illicit market in Q3 2020 and exceeding the illicit market's historical peak of $1.4 billion from Q1 2005. Meanwhile, medical cannabis spending has declined from its $161 million peak in Q4 2017 to current levels, highlighting how recreational legalization cannibalized medical programs. The legal cannabis sector contributed $8.922 billion to Canada's GDP as of June 2025, with monthly retail sales hitting $610 million. Canada's data shows what happens when governments actually commit to displacing illicit markets through accessible legal channels rather than protecting incumbent operators through artificial scarcity - legal markets can win on convenience and quality even when they can't compete on price. (StratCann)
The deeper pattern behind today’s moves — and why it matters next.
🧾 Context: Britain's National Crime Agency reports 378 arrests this year alone for cannabis smuggling by air passengers, with an estimated 15 tonnes seized at UK airports - already three times more than in 2023's total. The surge involves high-grade cannabis legally grown in California, Canada, and Thailand being smuggled through ordinary commercial flights by individual couriers carrying suitcases. Cannabis consultancy Hanway Associates noted that imported high-quality U.S. cannabis commands ten times its wholesale price in the UK, with wholesale benchmarks around $1,000 per pound in oversupplied California versus £80 for 3.5 grams in Britain. More than half of 2023 arrests involved travelers from U.S. airports, while this year 184 arrests related to Thai-origin cannabis, 75 from Canada, and 47 from the U.S.
🔎 What It Signals: This trafficking pattern reveals how state-legal cannabis markets inadvertently created international smuggling infrastructure when pricing arbitrage becomes extreme. California's chronic oversupply and regulatory burden pushed wholesale prices below production costs, making international smuggling economically attractive despite massive legal risks. The UK's status as the world's largest legal cannabis exporter while importing 100% of domestic medical cannabis creates regulatory contradictions that traffickers exploit. The courier model using individual passengers rather than traditional smuggling routes suggests organized networks have adapted to legal market dynamics. This pattern will likely replicate wherever significant price gaps exist between legal and illegal markets.
🧠 THC Group Take: California's regulatory challenges - massive legacy market that hasn’t migrated into legal, layers of oversight, etc. - are now Britain's enforcement problem. When you drive wholesale prices below production costs through overtaxation and licensing bottlenecks, international smuggling becomes the logical economic outlet. The 10x price differential between California wholesale and UK street prices creates profit margins that dwarf traditional drug trafficking risks. What's strategically significant isn't just the smuggling itself, but how state-legal markets with broken economics export their problems globally. Other oversupplied markets should expect similar patterns - when domestic demand can't support production capacity, criminal networks will find international customers willing to pay premium prices for legal-market quality.
From the hearing room to the comment section — we’re watching it all.
🏭 Italian company Aerolight is selling modular cannabis cultivation systems to European growers struggling with strict regulations and compliance costs, targeting operators who discovered that "compliance and efficiency are no longer optional" in Europe's regulated markets. Founder Marco Brunati noted that in Portugal, many operators invested heavily but faced bottlenecks when their product needed GMP certification for export, creating demand for plug-and-play pharmaceutical-grade systems. (MMJ Daily)
💰 High Times champions falling cannabis prices as consumer wins while the industry bleeds out, noting Michigan retail prices dropped 80% since 2020 to $83.71 per ounce and Oregon hit $3.33 per gram in July. Value brands like Old Pal sell California eighths for $10 before taxes, but Origins Council's Genine Coleman warns that consolidation and cost-cutting are creating "commodity-grade product" that drives consumers back to illicit markets. The piece misses the obvious irony: celebrating cheaper weed while California just hiked excise taxes to 19% shows how disconnected cannabis media remains from actual market dynamics. (High Times)
🌿 Forbes spotlights Anderson Valley's monthly cannabis tourism weekends as the sophisticated alternative to Amsterdam coffee shops, featuring heritage farm tours, craft marketplaces, and "consumption lounges with educated hosts and curated pairings." Writer Kim Westerman frames it as part of Mendocino's evolution from underground Emerald Triangle culture to "open, celebratory" cannabis tourism that mirrors the region's wine industry sophistication. The timing is strategic - as California's legal market struggles with oversupply and high taxes, premium cannabis tourism offers operators new revenue streams beyond traditional retail. (Forbes)
🔬 South African researchers just discovered flavoalkaloids - extremely rare hybrid compounds with pharmaceutical potential - hiding in cannabis leaves that most operations throw away as waste. Stellenbosch University chemists identified 79 phenolic compounds across three strains, with 25 never before reported in cannabis and 16 tentatively classified as these rare flavoalkaloids. The irony is perfect: while the industry obsesses over THC and CBD percentages, the real pharmaceutical goldmine might be sitting in dumpsters behind cultivation facilities. (SciTechDaily)